Clinical trial
Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
NCT00231192 · Children's Hospital of Philadelphia, Other · Withdrawn
Key facts
| NCT number | NCT00231192 |
|---|---|
| Title | Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes |
| Official title | Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes |
| Lead sponsor | Children's Hospital of Philadelphia, Other |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Diabetes |
| Intervention type | Drug |
| Interventions | Repaglinide and Insulin |
| Enrollment | 0 |
| Start date | Oct 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Oct 4, 2005 |
| Last update posted | Mar 12, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: